ArticleMethods in molecular biology (Clifton, N.J.)2026
Immunocompetent Preclinical Mouse Models of Brain Cancer.
Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brain cancer represents a critical public health issue with thousands of newly diagnosed patients per year in Europe and the United States facing a dismal prognosis. The tumor immune microenvironment (TIME) has recently emerged as a key player promoting brain tumor growth and shaping responses to therapy. Consequently, new strategies have been developed to target the immune component of brain cancers and foster ant-tumoral immune responses, although they have only proven effective in a subset of patients. Therefore, it is of utmost importance to understand the dynamic biology of the TIME upon therapeutic intervention. Here, I describe different immunocompetent preclinical mouse models of primary and metastatic brain cancer, which allow a comprehensive exploration of the role of the immune system in tumor progression and response to therapy.
Indexed as
Identifiers
41028266What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.